{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:27:27Z","timestamp":1767626847617,"version":"3.40.5"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"crossref","award":["MOST 107-2314-B-038-019-MY3"],"award-info":[{"award-number":["MOST 107-2314-B-038-019-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]},{"name":"grants form taipei medical university","award":["109TMU-TMUH-22"],"award-info":[{"award-number":["109TMU-TMUH-22"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Dual antiplatelet therapy (DAPT) is currently the standard treatment for the prevention of ischemic events after stent implantation. However, the optimal DAPT duration remains elusive for patients with chronic kidney disease (CKD). Therefore, we aimed to compare the effectiveness and safety between long-term and short-term DAPT after coronary stenting in patients with CKD.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This retrospective cohort study analyze data from the Taipei Medical University (TMU) Institutional and Clinical Database, which include anonymized electronic health data of 3 million patients that visited TMU Hospital, Wan Fang Hospital, and Shuang Ho Hospital. We enrolled patients with CKD after coronary stenting between 2008 and 2019. The patients were divided into the long-term (&gt;6 months) and short-term DAPT group (\u2264 6 months). The primary end point was major adverse cardiovascular events (MACE) from 6 months after the index date. The secondary outcomes were all-cause mortality and Thrombolysis in Myocardial Infarction (TIMI) bleeding.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 1899 patients were enrolled; of them, 1112 and 787 were assigned to the long-term and short-term DAPT groups, respectively. Long-term DAPT was associated with similar risk of MACE (HR: 1.05, 95% CI: 0.65\u20131.70, <jats:italic>P<\/jats:italic> = 0.83) compare with short-term DAPT. Different CKD risk did not modify the risk of MACE. There was also no significant difference in all-cause mortality (HR: 1.10, 95% CI: 0.75\u20131.61, <jats:italic>P<\/jats:italic> = 0.63) and TIMI bleeding (HR 1.19, 95% CI: 0.86\u20131.63, <jats:italic>P<\/jats:italic> = 0.30) between groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Among patients with CKD and coronary stenting, we found that long-term and short-term DAPT tied on the risk of MACE, all-cause mortality and TIMI bleeding.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0255645","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T17:36:01Z","timestamp":1628098561000},"page":"e0255645","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease"],"prefix":"10.1371","volume":"16","author":[{"given":"Chih-Chin","family":"Kao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai-Szu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-3513","authenticated-orcid":true,"given":"Ming-Tsang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3599-7758","authenticated-orcid":true,"given":"Yi-Cheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-5699","authenticated-orcid":true,"given":"Chih-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"issue":"23","key":"pone.0255645.ref001","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"F Feres","year":"2013","journal-title":"JAMA"},{"issue":"20","key":"pone.0255645.ref002","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"A Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"pone.0255645.ref003","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review","volume":"74","author":"MJ Sarnak","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"pone.0255645.ref004","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"GN Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"pone.0255645.ref005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"19","key":"pone.0255645.ref006","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS","volume":"67","author":"U Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"pone.0255645.ref007","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention","volume":"315","author":"RW Yeh","year":"2016","journal-title":"JAMA"},{"issue":"10073","key":"pone.0255645.ref008","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"F Costa","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"pone.0255645.ref009","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting","volume":"73","author":"F Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"pone.0255645.ref010","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"AS Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0255645.ref011","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2007.04.051","article-title":"Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry","volume":"50","author":"J Machecourt","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"pone.0255645.ref012","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/ki.1996.201","article-title":"Outcome and risk factors of ischemic heart disease in chronic uremia","volume":"49","author":"PS Parfrey","year":"1996","journal-title":"Kidney Int"},{"issue":"4","key":"pone.0255645.ref013","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000441-200304000-00002","article-title":"Cardiovascular mortality in end-stage renal disease","volume":"325","author":"AJ Collins","year":"2003","journal-title":"Am J Med Sci"},{"issue":"5","key":"pone.0255645.ref014","doi-asserted-by":"crossref","first-page":"e014294","DOI":"10.1136\/bmjopen-2016-014294","article-title":"Blood coagulation system in patients with chronic kidney disease: a prospective observational study","volume":"7","author":"MJ Huang","year":"2017","journal-title":"BMJ open"},{"issue":"15","key":"pone.0255645.ref015","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","article-title":"P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes","volume":"138","author":"L Bonello","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"pone.0255645.ref016","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","article-title":"Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies","volume":"15","author":"DE Weiner","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"pone.0255645.ref017","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The Risk of Major Hemorrhage with CKD","volume":"27","author":"AO Molnar","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"pone.0255645.ref018","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/ccd.26921","article-title":"Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial","volume":"90","author":"G Gargiulo","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"pone.0255645.ref019","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jacc.2015.10.034","article-title":"Impact of Bleeding on Quality of Life in Patients on DAPT: Insights From TRANSLATE-ACS","volume":"67","author":"AP Amin","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"pone.0255645.ref020","article-title":"Adverse Outcomes after Major Surgeries in Patients with Diabetes: A Multicenter Matched Study","volume":"8","author":"CS Lin","year":"2019","journal-title":"J Clin Med"},{"key":"pone.0255645.ref021","article-title":"Effect of weight loss on the estimated glomerular filtration rates of obese patients at risk of chronic kidney disease: the RIGOR-TMU study","author":"YC Lin","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2 Suppl 1","key":"pone.0255645.ref022","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"F National Kidney","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"pone.0255645.ref023","doi-asserted-by":"crossref","first-page":"e99645","DOI":"10.1371\/journal.pone.0099645","article-title":"Modification of diet in renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI) equations for Taiwanese adults","volume":"9","author":"LI Chen","year":"2014","journal-title":"PLoS One"},{"issue":"23","key":"pone.0255645.ref024","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"R Mehran","year":"2011","journal-title":"Circulation"},{"key":"pone.0255645.ref025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan\u2019s National Health Insurance Research Database: past and future","volume":"11","author":"CY Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"1","key":"pone.0255645.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial\u2014phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"AK Rao","year":"1988","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"pone.0255645.ref027","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0895-4356(96)00271-5","article-title":"Practical considerations on the use of the Charlson comorbidity index with administrative data bases","volume":"49","author":"W D\u2019Hoore","year":"1996","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"pone.0255645.ref028","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs","volume":"275","author":"T Sturmer","year":"2014","journal-title":"J Intern Med"},{"issue":"10","key":"pone.0255645.ref029","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/jgs.14253","article-title":"Use and Interpretation of Propensity Scores in Aging Research: A Guide for Clinical Researchers","volume":"64","author":"DH Kim","year":"2016","journal-title":"J Am Geriatr Soc"},{"issue":"35\u201336","key":"pone.0255645.ref030","first-page":"597","article-title":"Propensity Score: an Alternative Method of Analyzing Treatment Effects","volume":"113","author":"O Kuss","year":"2016","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"pone.0255645.ref031","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","article-title":"The Framingham predictive instrument in chronic kidney disease","volume":"50","author":"DE Weiner","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"pone.0255645.ref032","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ahj.2017.11.013","article-title":"Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease","volume":"197","author":"D Hwang","year":"2018","journal-title":"Am Heart J"},{"issue":"2","key":"pone.0255645.ref033","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2215\/CJN.04430416","article-title":"Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis","volume":"12","author":"YT Chen","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"pone.0255645.ref034","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2215\/CJN.12901018","article-title":"Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis","volume":"14","author":"TA Mavrakanas","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"pone.0255645.ref035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","article-title":"Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community","volume":"41","author":"G Manjunath","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"9731","key":"pone.0255645.ref036","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis C","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"pone.0255645.ref037","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"BK Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"pone.0255645.ref038","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial","volume":"321","author":"JY Hahn","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"pone.0255645.ref039","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"M Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"pone.0255645.ref040","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"H Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"pone.0255645.ref041","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jjcc.2016.07.017","article-title":"Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrel in Japanese patients","volume":"69","author":"T Nishi","year":"2017","journal-title":"J Cardiol"},{"issue":"1","key":"pone.0255645.ref042","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bcp.13436","article-title":"Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease","volume":"84","author":"H Wang","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"pone.0255645.ref043","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"PJ Best","year":"2008","journal-title":"American heart journal"},{"issue":"10","key":"pone.0255645.ref044","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","article-title":"Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial)","volume":"103","author":"A Dasgupta","year":"2009","journal-title":"Am J Cardiol"},{"issue":"6","key":"pone.0255645.ref045","doi-asserted-by":"crossref","first-page":"e39178","DOI":"10.1371\/journal.pone.0039178","article-title":"Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population","volume":"7","author":"DY Chen","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"pone.0255645.ref046","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial","volume":"37","author":"G Magnani","year":"2016","journal-title":"Eur Heart J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T17:36:35Z","timestamp":1628098595000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255645"}},"subtitle":[],"editor":[{"given":"Hitesh","family":"Raheja","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255645","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,8,4]]}}}